drugset / Trial / NCT01456039

A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)

NCT01456039

Phase 1/2 Completed 51 enrolled Celgene Corporation
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study was to assess efficacy, tolerability, safety and pharmacokinetics of Romidepsin in subjects with progressive or relapsed peripheral T-cell lymphoma

Timeline

Start
2011-12-01
Primary completion
2015-07-28
Completion
2018-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Romidepsin Peptide 9 mg/m2 Intravenous
Subject Romidepsin Peptide 14 mg/m2 Intravenous